fluvoxamine   Click here for help

GtoPdb Ligand ID: 7189

Synonyms: Luvox® | U-23000
Approved drug PDB Ligand Immunopharmacology Ligand
fluvoxamine is an approved drug (FDA (1994))
Compound class: Synthetic organic
Comment: Fluvoxamine is an antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) drug group.
Marketed formulations may contain fluvoxamine maleate (PubChem CID 9560989).
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: fluvoxamine

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 56.84
Molecular weight 318.16
XLogP 3.24
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES NCCON=C(c1ccc(cc1)C(F)(F)F)CCCCOC
Isomeric SMILES NCCO/N=C(/c1ccc(cc1)C(F)(F)F)\CCCCOC
InChI InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
No information available.
Summary of Clinical Use Click here for help
Used to treat major depressive episodes and obsessive compulsive disorder (OCD).

SARS-CoV-2 and COVID-19: The potential of fluvoxamine has been evaluated in symptomatic COVID-19 outpatients, with preliminary signs of benefit [5]. Fluvoxamine is propsed to modulate the effects of peripheral serotonin on systemic inflammation [10] in COVID-19 [2]. It may also have a beneficial effect via regulation of platelet-derived serotonin's role in recruiting innate immune cells (that express 5-HT receptors) to sites of inflammation [7].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
SSRIs increase serotonin levels at post-synaptic sites by inhibiting the pre-synaptic transporter, SERT (SLC6A4), normally involved in serotonin re-uptake. This enhances serotonergic neurotransmission with the clinical outcomes being improved mood and decreased anxiety. See the DrugBank link for further details.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04342663 A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection Phase 2 Interventional Washington University School of Medicine The preliminary signs of efficacy observed in this study (reduction in chance of clinical deterioration over 15 days in treatment arm) would need to be followed up in larger scale RCTs with a longer follow-up timescale. 5
External links Click here for help